Lista de obras - Odile Beyne-Rauzy - Dominio Público Uruguay

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2014

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

artículo científico publicado en 2019

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

artículo científico

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

artículo científico publicado en 2016

Bone Marrow Involvement in Systemic Lupus Erythematosus

artículo científico publicado en 2017

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases

scientific article published on 10 March 2011

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

artículo científico publicado en 2017

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

artículo científico publicado en 2013

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies

artículo científico publicado en 2009

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

artículo científico publicado en 2015

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

artículo científico publicado en 2008

Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis

artículo científico publicado en 2004

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

artículo científico publicado en 2011

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

artículo científico publicado en 2009

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

artículo científico publicado en 2015

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

artículo científico publicado en 2013

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

scientific article published on 01 January 2020

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort

artículo científico publicado en 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

artículo científico publicado en 2017

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

artículo científico publicado en 2012

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

artículo científico publicado en 2014

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

artículo científico publicado en 2007

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

artículo científico publicado en 2010

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

artículo científico publicado en 2013

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

artículo científico publicado en 2015

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

artículo científico publicado en 2010

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

artículo científico publicado en 2015

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

artículo científico publicado en 2011

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

artículo científico publicado en 2018

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

scientific article published on October 2009

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

artículo científico publicado en 2009

The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation.

artículo científico publicado en 2018

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

artículo científico publicado en 2012

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience

artículo científico publicado en 2011

Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells

artículo científico publicado en 2004

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

artículo científico publicado en 2017

Lista de obras de Odile Beyne-Rauzy

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Bone Marrow Involvement in Systemic Lupus Erythematosus

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience

Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.